TABLE 1.
Performance of PCDHGB7 methylation detection, hrHPV test, and TCT in early cervical cancer screening
| Negative | LSIL | HSIL | Cervical cancer | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample type: cervical smear | Neg/All | Per | Neg/All | Per | Pos/All | Per | Sensitivity | Specificity | PPV | NPV | Pos/All | Per | Sensitivity | Specificity | PPV | NPV |
| hrHPV Test | 31/87 | 35.6% | 9/110 | 8.2% | 155/164 | 94.5% | 94.50% | 20.30% | 49.70% | 81.60% | 22/23 | 95.7% | 95.70% | 20.30% | 12.30% | 97.60% |
| TCT (> = ASCUS) | 68/89 | 76.4% | 36/114 | 31.6% | 122/163 | 74.8% | 74.80% | 51.20% | 55.20% | 71.70% | 17/23 | 73.9% | 73.90% | 51.20% | 14.70% | 94.50% |
| DNA methylation | 89/91 | 97.8% | 110/120 | 91.7% | 114/168 | 67.9% | 67.90% | 94.30% | 90.50% | 78.70% | 24/25 | 96.0% | 96.00% | 94.30% | 66.70% | 99.50% |
| hrHPV and TCT (> = ASCUS) (any one positive as positive) | 27/89 | 30.3% | 2/112 | 1.8% | 163/165 | 98.8% | 98.80% | 14.40% | 48.70% | 93.50% | 23/23 | 100.0% | 100.00% | 14.40% | 11.80% | 100.00% |
| hrHPV and TCT (> = ASCUS) (both two positives as positive) | 72/87 | 82.8% | 43/112 | 38.4% | 114/162 | 70.4% | 70.40% | 57.80% | 57.60% | 70.60% | 16/23 | 69.6% | 69.60% | 57.80% | 16.00% | 94.30% |
| DNA methylation and hrHPV (any one positive as positive) | 31/87 | 35.6% | 8/112 | 7.1% | 163/166 | 98.2% | 98.20% | 19.60% | 50.50% | 92.90% | 25/25 | 100.0% | 100.00% | 19.60% | 13.50% | 100.00% |
| DNA methylation and hrHPV (both two positives as positive) | 89/91 | 97.8% | 111/118 | 94.1% | 106/166 | 63.9% | 63.90% | 95.70% | 92.20% | 76.90% | 21/23 | 91.3% | 91.30% | 95.70% | 70.00% | 99.00% |
| DNA methylation and TCT (> = ASCUS) (any one positive as positive) | 67/89 | 75.3% | 34/115 | 29.6% | 153/167 | 91.6% | 91.60% | 49.50% | 59.80% | 87.80% | 25/25 | 100.0% | 100.00% | 49.50% | 19.50% | 100.00% |
| DNA methylation and TCT (> = ASCUS) (both two positives as positive) | 90/91 | 98.9% | 112/119 | 94.1% | 83/164 | 50.6% | 50.60% | 96.20% | 91.20% | 71.40% | 16/23 | 69.6% | 69.60% | 96.20% | 66.70% | 96.70% |
| Methylation and TCT (> = ASCUS) and hrHPV (any one positive as positive) | 27/89 | 30.3% | 2/114 | 1.8% | 165/167 | 98.8% | 98.80% | 14.30% | 48.70% | 93.50% | 25/25 | 100.0% | 100.00% | 14.30% | 12.60% | 100.00% |
| Methylation and TCT (> = ASCUS) and hrHPV (any two positive as positive) | 71/87 | 81.6% | 40/111 | 36.0% | 149/164 | 90.9% | 90.90% | 56.10% | 63.10% | 88.10% | 23/23 | 100.0% | 100.00% | 56.10% | 20.90% | 100.00% |
| Methylation and TCT (> = ASCUS) and hrHPV (all three positive as positive) | 90/91 | 98.9% | 6/119 | 5.0% | 77/164 | 47.0% | 47.00% | 45.70% | 40.30% | 52.50% | 15/23 | 65.2% | 65.20% | 45.70% | 11.60% | 92.30% |
ASCUS, atypical squamous cells of undetermined significance; HSIL, high‐grade squamous intraepithelial lesion; LSIL, low‐grade squamous intraepithelial lesion; NPV, negative predictive values; Per., percentage; Pos, positive; PPV, positive predictive values; TCT, ThinPrep cytology test.